^
Association details:
| Biomarker: | PDZK1IP1 overexpression |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment
Published date:
09/23/2020
Excerpt:
Higher MAP17 levels were only slightly associated with worse DFS (p = 0.047) and PFS (p = 0.05), with no relevance regarding OS.
DOI:
https://doi.org/10.1038/s41392-020-00246-z
